Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Apr 10;16(7):813-815.
doi: 10.1016/j.jcin.2023.02.016.

MASTER-DAPT: A Further Step Toward Long-Term P2Y12 Blocker Monotherapy After PCI

Freek W A Verheugt  1
Affiliations
Free article
Editorial

MASTER-DAPT: A Further Step Toward Long-Term P2Y12 Blocker Monotherapy After PCI

Freek W A Verheugt. JACC Cardiovasc Interv. .
Free article
No abstract available

Keywords: P2Y(12) inhibitor; PCI; antiplatelet therapy; monotherapy.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Verheugt has received honoraria for consulting and presentations from AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, BMS/Pfizer, and Daiichi Sankyo.

Comment on

  • Abbreviated or Standard Antiplatelet Therapy in HBR Patients: Final 15-Month Results of the MASTER-DAPT Trial.
    Landi A, Heg D, Frigoli E, Vranckx P, Windecker S, Siegrist P, Cayla G, Włodarczak A, Cook S, Gómez-Blázquez I, Feld Y, Seung-Jung P, Mates M, Lotan C, Gunasekaran S, Nanasato M, Das R, Kelbæk H, Teiger E, Escaned J, Ishibashi Y, Montalescot G, Matsuo H, Debeljacki D, Smits PC, Valgimigli M; MASTER DAPT Investigators. Landi A, et al. JACC Cardiovasc Interv. 2023 Apr 10;16(7):798-812. doi: 10.1016/j.jcin.2023.01.366. JACC Cardiovasc Interv. 2023. PMID: 37045500 Clinical Trial.

MeSH terms

Substances

LinkOut - more resources